Drug intelligence / Profile preview

insulin + somatropin

Development stage: Preclinical
Lead developer: Novo Nordisk
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intramuscular, Intravenous

Overview

The combination of insulin and somatropin represents a therapeutic approach where both hormones are administered simultaneously. Somatropin is a recombinant human growth hormone that promotes growth and metabolic functions, while insulin regulates blood glucose levels. When used together, they can have enhanced anabolic effects compared to either agent alone. However, this combination requires careful monitoring as somatropin can affect insulin sensitivity and glucose metabolism.

Targets

INSR (Insulin receptor)GHR (Growth hormone receptor)

Beyond the preview

Go deeper on insulin + somatropin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin + somatropin.

Explore the full profile